Zydus Cadila gets USFDA nod for anti-dementia drug
New Delhi: Drug firm Zydus Cadila on Friday said it has received the final nod from the US health regulator to market Donepezil Hydrochloride tablets used for the treatment of dementia of the Alzheimer's type in the American market.
The company has received the final approval from the United States Food and Drug Administration (USFDA) to market Donepezil Hydrochloride tablets in the strength of 23 mg, Zydus Cadila said in a statement.
The drug will be manufactured at the group's formulations manufacturing facility at Moraiya in Ahmedabad, Zydus Cadila said.
The tablets are indicated for the treatment of dementia of the Alzheimer's disease, it added.
The group now has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process, Zydus Cadila said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd